Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.
Financière de Tubize (ENXTBR:TUB) recently reported half year 2026 net income of €100.76 million compared with €95.57 million a year earlier, drawing fresh attention to how the holding company's earnings feed into its current valuation.
See our latest analysis for Financière de Tubize.
The latest half year earnings have come at a time when Financière de Tubize's share price has been under pressure, with the 30-day share price return down 13.24% and the year to date share price return down 8.06%. However, the 1-year total shareholder return is 33.37% and the 3-year total shareholder return is 175.55%, which points to strong longer term gains despite recent weakness.
If this earnings update has you thinking about where else to put fresh capital to work, it could be a good moment to scan opportunities through the 128 healthcare AI stocks
Financière de Tubize has given investors a mix of recent share price weakness and strong multi year returns. The key issue now is whether most of the upside is already behind the stock or still ahead, as valuation comes into focus.
On the latest figures, Financière de Tubize trades on a P/E of 92.6x, which sits against a last close price of €194 and clearly points to a rich earnings multiple compared with peers.
The P/E ratio compares the company's share price with its earnings per share and is a common way investors gauge how much they are paying for each unit of current earnings. For a holding company like Financière de Tubize that primarily owns a stake in UCB, a very high P/E can indicate that the market is putting a strong value on the quality or stability of those earnings rather than on rapid growth.
Here, the 92.6x P/E is much higher than both the European pharmaceuticals industry average of 20.8x and the peer average of 25.6x. That kind of premium suggests investors are willing to pay several times more than the sector for each euro of earnings, even though earnings have declined on average over the past five years and recent growth has not outpaced the wider pharmaceuticals group.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-earnings of 92.6x (OVERVALUED)
However, there are clear risks if Financière de Tubize's high P/E multiple contracts, or if UCB's fundamentals weaken, or if sentiment toward the healthcare sector worsens.
Find out about the key risks to this Financière de Tubize narrative.
Alongside the rich 92.6x P/E, the Simply Wall St DCF model points to a future cash flow value of €30.69 per share compared with the current €194 price. That suggests Financière de Tubize trades well above this estimate. The real question is which signal you trust more when you think about risk.
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Financière de Tubize for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 259 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
If this mix of rich valuation signals and highlighted risks around Financière de Tubize leaves you unsure, act quickly and review the full picture yourself. To see exactly what could be weighing on sentiment, take a closer look at the 3 important warning signs.
If Financière de Tubize has sharpened your eye for valuation and risk, do not stop here. Broaden your watchlist now so you are not late to the next opportunity.
Target resilient companies that aim to preserve capital through swings in sentiment by scanning 303 resilient stocks with low risk scores with the Simply Wall St Screener.
Spot potential bargains trading at attractive valuations by running the 259 high quality undervalued stocks and compare ideas before committing fresh capital.
Build a watchlist of potential income candidates by filtering for 433 dividend fortresses that could complement growth focused holdings.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include TUB.BR.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]